Kurume University   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Kurume Japan (1946)

Organization Overview

First Clinical Trial
2002
NCT00190528
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Department of Medicine, Division of Cardiovascular Medicine, Kurume University School of Medicine | Kurume University | Kurume University School of Medicine | The Department of Pediatrics and Child Health Kurume University School of Medicine | The Third Department of Internal Medicine, Kurume University

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 3)

Autism Spectrum Disorder (Phase 3)

Autistic Disorder (Phase 3)

Child Development Disorders, Pervasive (Phase 3)

Diabetes Complications (Phase 4)

Disease (Phase 3)

Essential Hypertension (Phase 4)

Hypertension (Phase 4)

Inflammation (Phase 4)

Neurodevelopmental Disorders (Phase 3)

Parasomnias (Phase 3)

Rectal Neoplasms (Phase 2)

Sleep Wake Disorders (Phase 3)

Uterine Cervical Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 14
  • # of Trial APIs: 28